awmsg logo



cetuximab (Erbitux®)


Reference No. 2407

Publication date:
05/01/2016


Appraisal information

cetuximab (Erbitux®) 5 mg/ml solution for infusion


Company: Merck Serono Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 09/09/2015
AWMSG meeting date: 09/12/2015
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 4315
Ministerial ratification: 30/12/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA439) NICE GUIDANCE ISSUED MARCH 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Cetuximab (Erbitux®) is recommended as an option for restricted use within NHS Wales for the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy or in combination with FOLFOX. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised. Cetuximab (Erbitux®) is not recommended for use within NHS Wales for the treatment of patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download